(Q38239532)

31 August 2017

title

Insulin and GH-IGF-I axis: endocrine pacer or endocrine disruptor? (English)

1 reference

31 August 2017

1 reference

R Berardelli

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25118998%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

C Gazzaruso

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25118998%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

publication date

14 August 2014

1 reference

31 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25118998%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

volume

52

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25118998%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25118998%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

page(s)

433-443

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25118998%20AND%20SRC:MED&resulttype=core&format=json

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collab

3 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Inadequacies of current approaches to prediabetes and diabetes prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Economic costs of diabetes in the U.S. in 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

SMART diabetes: the way to go (Safe and Multifactorial Approach to reduce the Risk for Therapy in diabetes).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

New guidelines for metabolic targets in diabetes: clinician's opinion does matter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

The source of cerebral insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Insulin in the brain: sources, localization and functions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Identification of insulin in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Insulin in central nervous system: more than just a peripheral hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Development of brain insulin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Cell signaling by receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

New twist on neuronal insulin receptor signaling in health, disease, and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Differential permeability of the blood-brain barrier to two pancreatic peptides: insulin and amylin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Memory function and brain glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Brain insulin receptors and spatial memory. Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

The role of insulin in human brain glucose metabolism: an 18fluoro-deoxyglucose positron emission tomography study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Insulin receptors and insulin action in the brain: review and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Cerebral glucose metabolism in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Brain contains a functional glucose-6-phosphatase complex capable of endogenous glucose production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Central insulin action in energy and glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Metabolic sensing neurons and the control of energy homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Central nervous system control of food intake and body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Insulin receptor and ageing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Insulin neuroprotection against oxidative stress in cortical neurons--involvement of uric acid and glutathione antioxidant defenses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Neurodegenerative disorders associated with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Biphasic effects of stress upon GLUT8 glucose transporter expression and trafficking in the diabetic rat hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Effects of changes in peripheral and cerebral glucose metabolism on locomotor activity, learning and memory in adult male rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Insulin signaling pathways in time and space.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Ras activation by insulin and epidermal growth factor through enhanced exchange of guanine nucleotides on p21ras

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Cellular mechanisms of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Mitogenic action of insulin: friend, foe or 'frenemy'?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Insulin resistance: an adaptive mechanism becomes maladaptive in the current environment - an evolutionary perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Insulin sensitivity: modulation by nutrients and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Inflammation and metabolic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Disordered lipid metabolism and the pathogenesis of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Lipodystrophies: rare disorders causing metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Markers of mitochondrial biogenesis and metabolism are lower in overweight and obese insulin-resistant subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Effects of pyridostigmine on spontaneous and growth hormone-releasing hormone stimulated growth hormone secretion in children on daily glucocorticoid therapy after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Influence of thyroid hormones on the regulation of growth hormone secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Glucocorticoids and the regulation of growth hormone secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Growth hormone, insulin-like growth factors, and the skeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Serum levels of insulin-like growth factor I and its binding proteins in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Signalling through IGF-I and insulin receptors: where is the specificity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Biological and immunological properties of insulin-like growth factors (IGF) I and II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Receptors for insulin and insulin-like growth factor-I can form hybrid dimers. Characterisation of hybrid receptors in transfected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Characterization of human placental insulin-like growth factor-I/insulin hybrid receptors by protein microsequencing and purification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Molecular and cellular aspects of the insulin-like growth factor I receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Developmental expression of receptors for insulin, insulin-like growth factor I (IGF-I), and IGF-II in rat skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle-aged adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Comparison of the effects of recombinant human insulin-like growth factor-I and insulin on glucose and leucine kinetics in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Insulin action and glucose metabolism in nondiabetic control and NIDDM subjects. Comparison using human skeletal muscle cell cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Specific binding of human growth hormone but not insulin-like growth factors by human adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Alterations in the growth hormone-insulin-like growth factor axis in insulin dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

The association between IGF-I and insulin resistance: a general population study in Danish adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Effect of strict glycemic control in patients with diabetes mellitus on frequency of macrovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Hyperglycemia and vascular metabolic memory: truth or fiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Plasma concentration of IGF-I is independently associated with insulin sensitivity in subjects with different degrees of glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

The role of IGF-system in vascular insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

IGF-1 and retinopathy of prematurity in the preterm infant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Inhibition of vascular smooth muscle cell growth through antisense transcription of a rat insulin-like growth factor I receptor cDNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

The role of IGF-I and its binding proteins in the development of type 2 diabetes and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Endogenous hormones and carotid atherosclerosis in elderly men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

IGF binding protein 1 predicts cardiovascular morbidity and mortality in patients with acute myocardial infarction and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH--an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Diagnosis and treatment of acromegaly complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Intraperitoneal insulin delivery to patients with type 1 diabetes results in higher serum IGF-I bioactivity than continuous subcutaneous insulin infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Insulin treatment normalizes reduced free insulin-like growth factor-I concentrations in diabetic children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Insulin-like growth factor I receptors are more abundant than insulin receptors in human micro- and macrovascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Increased expression of insulin/insulin-like growth factor-I hybrid receptors in skeletal muscle of noninsulin-dependent diabetes mellitus subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Evidence for glucose/hexosamine in vivo regulation of insulin/IGF-I hybrid receptor assembly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Expression of insulin/IGF-I hybrid receptors is increased in skeletal muscle of patients with chronic primary hyperinsulinemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Effect of insulin analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1 and M2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Combined randomised controlled trial experience of malignancies in studies using insulin glargine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Insulin Glargine and Cancer Risk: An Opinion Statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Insulin analogues and cancer risk: cause for concern or cause célèbre?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Novel insulin analogues and its mitogenic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Cancer specific mortality in insulin-treated type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Impact of glucose-lowering agents on the risk of cancer in type 2 diabetic patients. The Barcelona case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Basal insulin analogues in the management of diabetes mellitus: What progress have we made?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Recombinant human insulin-like growth factor-I (rhIGF-I) therapy in adults with type 1 diabetes mellitus: effects on IGFs, IGF-binding proteins, glucose levels and insulin treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Effects of insulin-like growth factor-I on glucose tolerance, insulin levels, and insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Changes in insulin sensitivity induced by short-term growth hormone (GH) and insulin-like growth factor I (IGF-I) treatment in GH-deficient adults are not associated with changes in adiponectin levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Beneficial metabolic effects of insulin-like growth factor I in patients with severe insulin-resistant diabetes type A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Low circulating levels of IGF-1 in healthy adults are associated with reduced β-cell function, increased intramyocellular lipid, and enhanced fat utilization during fasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

The relationship between insulin secretion, the insulin-like growth factor axis and growth in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Defective insulin secretion in pancreatic beta cells lacking type 1 IGF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

New insights into the roles of insulin/IGF-I in the development and maintenance of beta-cell mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Insulin-like growth factors and pancreas beta cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Tyrosine kinases play a permissive role in glucose-induced insulin secretion from adult rat islets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Pancreatic-specific inactivation of IGF-I gene causes enlarged pancreatic islets and significant resistance to diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Insulin-like growth factor I has a direct effect on glucose and protein metabolism, but no effect on lipid metabolism in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

The effects of a specific growth hormone antagonist on overnight insulin requirements and insulin sensitivity in young adults with Type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Continuous glucose monitoring in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

HbA1c for screening and diagnosis of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

The Effects of Repeated Daily Recombinant Human Insulin-like Growth Factor I Administration in Adolescents with Type 1 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6

Effects of Recombinant Human IGF-I/IGF-Binding Protein-3 Complex on Glucose and Glycerol Metabolism in Type 1 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-014-0635-6